Drug: Ganitumab (AMG 479, NantCell)
Status: Granted orphan drug designation for the treatment of patients with Ewing sarcoma
Significant Information:
- Insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody
- Inhibits cancer cell proliferation via disruption of the P13K/Akt and MAPK pathways
- Phase III trial is currently evaluating the use of ganitumab to treat patients with newly diagnosed Ewing sarcoma
—Based on a company press release